Catalent has entered into a long-term commercial supply agreement with BeiGene, Ltd., a biopharmaceutical company focused molecularly-targeted and immuno-oncology drugs to treat cancer. Catalent will manufacture BRUKINSA (zanubrutinib), a Bruton’s tyrosine kinase (BTK) inhibitor that has recently received accelerated approval from the U.S. FDA, as a treatment for mantle cell lymphoma (MCL) in adult patients who have received at least one prior therapy. BRUKINSA is now commercially available in t...